Metastatic breast cancer trials in United Kingdom

In United Kingdom 36 Also abroad 610

36 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Edinburgh, London, Manchester
Age
18 years and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
Phase 1/2Taking people
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Where
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
Age
18 years and over
People
380 worldwide
Run by
BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00
Phase 2Taking people
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Where
Cardiff, London, Nottingham
Age
18 years and over
People
120 worldwide
Run by
ALX Oncology Inc.
See details and how to joinNCT07007559
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Glasgow, London
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Bath, Cardiff, London, Manchester, Nottingham, Swindon, Taunton, Truro
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Leicester, Liverpool, London, Manchester, Montacute
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
Age
18 years and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
Phase 3Taking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
Phase 3Taking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
Leicester, London, Manchester
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
Phase 2Taking people
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Where
Blackpool, Harlow, Northwood, Middlesex, Oxford
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07368998 · EU 2025-522805-39-00
Phase 2Taking people
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Where
Leicester, London, Manchester
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 3Taking people
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Where
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
Age
18 years and over
People
600 worldwide
Run by
LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Basingstoke, Blackpool, Dumfries, Edinburgh, Harlow, Livingston, London, Maidstone, Northwood, Oxford, Preston, Winchester
Age
18 years and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
Phase 1/2Taking people
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Where
Glasgow, London
Age
18 years and over
People
181 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06686394
Phase 2Taking people
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Where
Southampton
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Coventry, London, Maidstone, Peterborough, Sutton, Taunton
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Belfast, Blackpool, Colchester, Essex, Northwood, Nottingham, Oxford
Age
18 years and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Blackpool, London, Londonderry, Nottingham, Truro
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 3Taking people
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
Bathgate, Cambridge, Cottingham, Glasgow, Leeds, Maidstone, Rickmansworth, Taunton
Age
18 years and over
People
1,180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
No phaseTaking people
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
Where
London, Oxford
Age
16 years to 100 years
People
42
Run by
Imperial College London
See details and how to joinNCT06611306
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Glasgow, Scotland, London, Newcastle upon Tyne
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
No phaseNot yet taking people in United Kingdom
Examining a New Insomnia Treatment for People Living With Secondary Breast Cancer.
Where
Glasgow
Age
18 years and over
People
50
Run by
University of Strathclyde
See details and how to joinNCT07859098
Phase 2Taking people
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Where
Cambridge, London, Manchester
Age
18 years and over
People
24 worldwide
Run by
AstraZeneca
See details and how to joinNCT07427394